Lexeo Therapeutics rises after positive trial results for heart disease drug

Lexeo Therapeutics

07/10/2025 12:04

** Shares of drug developer Lexeo Therapeutics LXEO.O rise 29% to $8.35 premarket

** Lexeo says the U.S. FDA is open to letting the company combine results from its ongoing studies and a planned trial to seek accelerated approval for its experimental gene therapy, LX2006, for Friedreich's ataxia cardiomyopathy

** Friedreich's ataxia cardiomyopathy is a heart condition where the heart muscle gets thickened and stiff due to a genetic disorder called Friedreich's ataxia

** Lexeo also reports new interim results from 16 participants who have been followed for more than six months

** Among six patients who started with abnormally large heart muscle size — a key problem in this disease - on average, heart muscle size fell 18% at six months and 23% at 12 months, above the company's FDA-aligned target of a 10% drop

** As of last close, LXEO stock was down 1.7% YTD

 (Reporting by Padmanabhan Ananthan)

 ((Padmanabhan.Ananthan@thomsonreuters.com))